Page 49 - Recognizing axial spondyloarthritis - Janneke de Winter

B Name study Gespic
Kiltz
Desir
SCQM
SPACE
Esperanza
Wallis
ESPAC
Pooled psoriasis prevalence Pooled prevalence differenced
Nr‐axSpA N 226 44 295 232 93 182 73 132 1242
Prevalence in nr‐axSpA, % (95% CI)
9.7 (5.9‐13.6) 11.4 (2.0‐20.7) 14.2 (10.3‐18.2)
9.1 (5.4‐12.7)
8.6 (1.4‐15.8) 13.7 (8.7‐18.7) 9.6 (2.8‐16.3) 6.8 (2.5‐11.1) 10.9 (9.1‐13.0) ‐0.7 (‐2.9‐1.6)
Prevalence in nr‐axSpA, % (95% CI)
1.8 (0.1‐3.5) 6.8 (0‐14.3) 3.1 (1.1‐5.0) 7.3 (4.0‐10.7) 5.2 (‐0.5‐10.9) 1.7 (0‐3.5) 10.1 (3.8‐18.1) 1.5 (‐0.6‐3.6) 4.1 (2.3‐6.5) 1.4 (‐0.1‐2.9)
AS N 236 56 180 838 25 109 639 155 2236
AS N 236 56 180 838 23 109 639 155 2236
Prevalence in
AS % (95% CI)
10.2 (6.3‐14.0) 17.1 14.3 (5.1‐23.5) 3.0 18.9 (13.2‐24.6) 10.5
DISEASE MANIFESTATIONS IN AXIAL SPA
Weight Prevalencedifference, %(95%CI) % M‐H, random effects
C Name study Gespic
Kiltz
Desir
SCQM
SPACE
Esperanza
Wallis
ESPAC
Pooled IBD prevalence Pooled prevalence difference
Nr‐axSpA N 226 44 295 232 58 182 73 132 1242
Prevalence in AS, % (95% CI)
Weight Prevalence difference, % (95% CI) % M‐H, random effects
7.4 (5.6‐9.2) 30.4 17.3 (1.9‐32.9) 1.8 7.3 (2.4‐12.4) 10.4 9.4 (7.1‐11.7) 10.1 5.2 (1.7‐8.6) 16.7 10.2 (7.5‐13.2) 100%
‐20 ‐10 0 10 20
nr‐axSpA AS
2.5 (0.5‐4.6) 30.1 5.4 (0‐11.3) 2.3 7.8 (3.9‐11.7) 11.0 9.3 (7.8‐11.3) 13.9 8.7 (‐2.8‐20.2) 1.3 5.5 (1.2‐9.8) 9.7
12.5 (10.0‐15.1) 3.6 1.3 (‐0.5‐3.1) 28.1 6.4 (3.6‐9.7) 100.0
Figure 3. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.
A: pooled prevalence difference of uveitis in patients with ankylosing spondylitis versus non-radiographic axial SpA
B: pooled prevalence difference of psoriasis in patients with ankylosing spondylitis versus non-radiographic axial SpA
C: pooled prevalence difference of IBD in patients with ankylosing spondylitis versus non- radiographic axial SpA
GESPIC GErman SPondyloarthritis Inception Cohort; SCQM Swiss Clinical Quality Management; SPACE SPondyloArthritis Caught Early; M-H Mantel-Haenszel, IBD inflammatory bowel disease
DISCUSSION
In this meta-analysis we have shown that peripheral (arthritis, enthesitis, dactylitis) and extra-articular (uveitis, psoriasis, inflammatory bowel disease) disease manifestations are frequent and, with the exception of a history of uveitis, equally prevalent in AS and nr-axSpA.
Our data of peripheral disease are consistent with earlier published data of
‐20 ‐10 0 10 20
nr‐axSpA AS
47
THREE